Tumour necrosis factor-alpha increases extravasation of virus particles into tumour tissue by activating the Rho A/Rho kinase pathway

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61389013%3A_____%2F11%3A00368414" target="_blank" >RIV/61389013:_____/11:00368414 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.jconrel.2011.08.022" target="_blank" >http://dx.doi.org/10.1016/j.jconrel.2011.08.022</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jconrel.2011.08.022" target="_blank" >10.1016/j.jconrel.2011.08.022</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Tumour necrosis factor-alpha increases extravasation of virus particles into tumour tissue by activating the Rho A/Rho kinase pathway

Popis výsledku v původním jazyce

Tumour Necrosis Factor alpha (TNF) is a cytokine with known vascular permeabilising activity. It is employed during isolated limb perfusion to enhance delivery of chemotherapeutic drugs into tumour tissue. The use of lytic viruses provides a new approachto cancer treatment that is limited by the low efficiency of extravasation of viral particles into tumours. TNF enhances the delivery of virus particles through the endothelial layer to tumour cells in vitro and in vivo. Intravenous administration of TNF resulted in a 3- to 6-fold increase in EL4 tumour uptake of Evans Blue/Albumin, adenovirus and long-circulating polymer coated adenovirus. Endothelial permeabilisation could be suppressed in vitro and in vivo by Y-27632, a Rho kinase inhibitor, withoutinhibiting viral infection. TNF enhances the delivery of virus particles into tumours through a Rho A/Rho kinase dependent mechanism and may be a new strategy for increasing the delivery of oncolytic viruses and other therapeutic agents.

Název v anglickém jazyce

Tumour necrosis factor-alpha increases extravasation of virus particles into tumour tissue by activating the Rho A/Rho kinase pathway

Popis výsledku anglicky

Tumour Necrosis Factor alpha (TNF) is a cytokine with known vascular permeabilising activity. It is employed during isolated limb perfusion to enhance delivery of chemotherapeutic drugs into tumour tissue. The use of lytic viruses provides a new approachto cancer treatment that is limited by the low efficiency of extravasation of viral particles into tumours. TNF enhances the delivery of virus particles through the endothelial layer to tumour cells in vitro and in vivo. Intravenous administration of TNF resulted in a 3- to 6-fold increase in EL4 tumour uptake of Evans Blue/Albumin, adenovirus and long-circulating polymer coated adenovirus. Endothelial permeabilisation could be suppressed in vitro and in vivo by Y-27632, a Rho kinase inhibitor, withoutinhibiting viral infection. TNF enhances the delivery of virus particles into tumours through a Rho A/Rho kinase dependent mechanism and may be a new strategy for increasing the delivery of oncolytic viruses and other therapeutic agents.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

CD - Makromolekulární chemie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Controlled Release

ISSN

0168-3659

e-ISSN

—

Svazek periodika

156

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

9

Strana od-do

381-389

Kód UT WoS článku

000298555000014

EID výsledku v databázi Scopus

—